Gland Pharma Ltd

With a decisive surge to Rs 3041.95 on 7 Sep 2026, Gland Pharma Ltd has reached a new 52-week high, extending its impressive 58.44% gain over the past year. This milestone comes amid a broader market downturn, underscoring the stock's strong technical momentum and resilience.

Gland Pharma Ltd, a prominent player in the Pharmaceuticals & Biotechnology sector, witnessed significant trading activity on 4 September 2026, with a total traded value exceeding ₹41,873.9 lakhs. Despite a slight dip in its share price and a recent downgrade in its Mojo Grade from Buy to Hold, the stock remains a focal point for institutional investors and market participants due to its liquidity and sustained interest.

Gland Pharma Ltd has witnessed a notable shift in its technical momentum, moving from a mildly bullish stance to a more confident bullish trend. Supported by robust price action and positive signals from key technical indicators such as MACD, Bollinger Bands, and moving averages, the pharmaceutical company’s stock is showing renewed strength despite mixed broader market conditions.

Gland Pharma Ltd, a prominent player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Buy to Hold as of 2 September 2026. This adjustment reflects a nuanced reassessment across four critical parameters: quality, valuation, financial trend, and technical indicators. Despite strong recent financial performance and market-beating returns, evolving technical signals and valuation concerns have tempered the overall outlook.

Gland Pharma Ltd has experienced a subtle shift in its technical momentum, moving from a bullish to a mildly bullish stance as of early September 2026. Despite a slight dip in daily price, the stock’s technical indicators present a complex picture, with bullish signals from MACD and moving averages contrasting with bearish cues from the monthly RSI and on-balance volume. This nuanced technical landscape warrants a detailed analysis for investors seeking clarity on the stock’s near-term trajectory.

Gland Pharma Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 29 May 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 28 August 2026, providing investors with the most up-to-date insight into the stock’s fundamentals, returns, and technical outlook.

Gland Pharma Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 29 May 2026. While the rating change occurred on that date, the analysis and financial metrics presented here reflect the stock's current position as of 17 August 2026, providing investors with the latest insights into the company’s performance and outlook.

Surging past Rs 2993.8 on 14 Aug 2026, Gland Pharma Ltd has marked a significant milestone by reaching a fresh 52-week high, propelled by a confluence of robust technical indicators and sustained price momentum.

Gland Pharma Ltd has witnessed a notable shift in its valuation parameters, moving from a very expensive to an expensive rating, reflecting a subtle but meaningful improvement in price attractiveness. This change comes amid robust stock performance and evolving sector dynamics, positioning the company favourably against its pharmaceutical peers and broader market benchmarks.

Gland Pharma Ltd, a prominent player in the Pharmaceuticals & Biotechnology sector, reached a significant milestone on 11 August 2026 by touching a new 52-week high of Rs.2989.25. This achievement underscores the stock’s strong momentum amid a mixed market environment, reflecting robust financial performance and sustained investor confidence.

Gland Pharma Ltd witnessed a remarkable surge in trading activity on 11 Aug 2026, emerging as one of the most actively traded stocks by value in the Pharmaceuticals & Biotechnology sector. The stock soared 9.07% intraday, hitting a fresh 52-week high of Rs. 2,979, driven by robust institutional participation and strong order flow, signalling renewed investor confidence in this small-cap pharmaceutical player.

Gland Pharma Ltd commenced trading on 11 Aug 2026 with a notable gap up, opening 6.53% higher than its previous close, signalling robust positive momentum in the Pharmaceuticals & Biotechnology sector. The stock outperformed the broader market and its sector peers, hitting a new 52-week high of Rs.2950 during intraday trade.

The Sensex declined 0.45% on 11 Aug 2026, yet Gland Pharma Ltd surged 8.05%, marking a 6.97-percentage-point outperformance over its Pharmaceuticals & Biotechnology sector. This sharp single-session gain rewrites the short-term narrative for the stock, which also hit a new 52-week high of Rs 2929.65 during the day.

With a decisive surge to Rs 2675.15 on 10 Aug 2026, Gland Pharma Ltd has reached a fresh 52-week high, propelled by a confluence of bullish technical indicators and sustained price momentum that outpaces its sector and the broader market.

Gland Pharma Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 29 May 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 06 August 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Gland Pharma Ltd has witnessed a notable shift in its valuation parameters, moving from an expensive to a very expensive rating, despite delivering robust returns well above the Sensex benchmark. This change reflects evolving market perceptions and valuation multiples in the Pharmaceuticals & Biotechnology sector, prompting investors to reassess the stock’s price attractiveness in the context of its financial performance and peer comparisons.